These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8480686)

  • 21. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
    Erb N; Harms DO; Janka-Schaub G
    Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapeutic metabolism presenting as a recalcitrant case of hand-foot syndrome and mucositis.
    Kwan KR; Skokan S; Blesh-Boren T; Vogel J; Harter N; Ford JB
    J Oncol Pharm Pract; 2024 Apr; 30(3):584-588. PubMed ID: 38204187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia.
    Hayder S; Björk O; Lafolie P
    Acta Paediatr Scand; 1990; 79(8-9):832-7. PubMed ID: 2239280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
    J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children.
    Koren G; Ferrazini G; Sulh H; Langevin AM; Kapelushnik J; Klein J; Giesbrecht E; Soldin S; Greenberg M
    N Engl J Med; 1990 Jul; 323(1):17-21. PubMed ID: 2355954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia.
    Adamson PC; Zimm S; Ragab AH; Balis F; Steinberg SM; Kamen BA; Vietti TJ; Gillespie A; Poplack DG
    Cancer Chemother Pharmacol; 1992; 30(2):155-7. PubMed ID: 1600597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of allopurinol to manage skewed 6-mercaptopurine metabolism in pediatric maintenance acute lymphoblastic leukemia treatment.
    Lines M; Kemper RM; Wallace J; Alexander T; Echols C; Garner LM; Kaplan JB; Thompson P; Crona DJ; Phillips K
    Eur J Haematol; 2024 Nov; 113(5):584-592. PubMed ID: 38989562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequence-, time- and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts.
    Bökkerink JP; Bakker MA; Hulscher TW; De Abreu RR; Schretlen ED; van Laarhoven JP; De Bruyn CH
    Biochem Pharmacol; 1986 Oct; 35(20):3549-55. PubMed ID: 2429667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ω-3 fatty acids as an adjuvant therapy ameliorates methotrexate-induced hepatotoxicity in children and adolescents with acute lymphoblastic leukemia: A randomized placebo-controlled study.
    Elbarbary NS; Ismail EA; Farahat RK; El-Hamamsy M
    Nutrition; 2016 Jan; 32(1):41-7. PubMed ID: 26421385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group.
    Bleyer WA; Sather HN; Nickerson HJ; Coccia PF; Finklestein JZ; Miller DR; Littman PS; Lukens JN; Siegel SE; Hammond GD
    J Clin Oncol; 1991 Jun; 9(6):1012-21. PubMed ID: 2033414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
    Adam de Beaumais T; Dervieux T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):653-8. PubMed ID: 20033410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
    Lange BJ; Blatt J; Sather HN; Meadows AT
    Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of mercaptopurine (6MP) metabolites and 6MP metabolic key-enzymes in childhood acute lymphoblastic leukemia.
    Wojtuszkiewicz A; Barcelos A; Dubbelman B; De Abreu R; Brouwer C; Bökkerink JP; de Haas V; de Groot-Kruseman H; Jansen G; Kaspers GL; Cloos J; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):422-33. PubMed ID: 24940700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study.
    Camitta B; Leventhal B; Lauer S; Shuster JJ; Adair S; Casper J; Civin C; Graham M; Mahoney D; Munoz L
    J Clin Oncol; 1989 Oct; 7(10):1539-44. PubMed ID: 2778483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
    J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of acute lymphocytic leukemia differentiation by maintenance therapy.
    Lin TL; Vala MS; Barber JP; Karp JE; Smith BD; Matsui W; Jones RJ
    Leukemia; 2007 Sep; 21(9):1915-20. PubMed ID: 17611566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of base-excision repair in the treatment of childhood acute lymphoblastic leukaemia with 6-mercaptopurine and high doses of methotrexate.
    Stanczyk M; Sliwinski T; Trelinska J; Cuchra M; Markiewicz L; Dziki L; Bieniek A; Bielecka-Kowalska A; Kowalski M; Pastorczak A; Szemraj J; Mlynarski W; Majsterek I
    Mutat Res; 2012 Jan; 741(1-2):13-21. PubMed ID: 22064329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia.
    Levinsen M; Shabaneh D; Bohnstedt C; Harila-Saari A; Jonsson OG; Kanerva J; Lindblom A; Lund B; Andersen EW; Schmiegelow K;
    Eur J Haematol; 2012 Jan; 88(1):78-86. PubMed ID: 21854453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fasting hypoglycemia is common during maintenance therapy for childhood acute lymphoblastic leukemia.
    Halonen P; Salo MK; Mäkipernaa A
    J Pediatr; 2001 Mar; 138(3):428-31. PubMed ID: 11241057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.